Literature DB >> 15814283

Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches.

Oyedele A Adeyi1, Alin L Girnita, Judy Howe, Marilyn Marrari, Yehia Awadalla, Medhat Askar, Joan Martell, Adrian Zeevi, Ron Shapiro, Michael Nalesnik, Parmjeet Randhawa, Anthony J Demetris, René J Duquesnoy.   

Abstract

This study deals with HLA-mismatched kidney transplants that have been removed following rejection. Sera from 27 patients were screened for HLA-specific antibodies by direct complement-dependent lymphocytotoxicity with HLA-typed cell panels. Circulating donor-specific antibodies were detected in 3 cases (11%) before and in 26 cases (97%) after allograft nephrectomy. These findings demonstrate the production of donor-specific antibodies in patients with rejected transplants, but in most cases, they were undetectable before nephrectomy, because the graft had adsorbed them. With an HLAMatchmaker-based serum analysis program, we observed restricted antibody specificity patterns against amino acid triplet-defined epitopes on donor HLA-A,B antigens. Many donor triplets were non-reactive while others were apparently recognized by antibodies. In some patients, the donor triplet specific antibodies persisted for a long time whereas in many other patients, they became undetectable after a few months. The characterization of the antibody specificity profiles of post-allograft nephrectomy sera is clinically useful in defining criteria of HLA mismatch acceptability for sensitized patients awaiting another transplant. It provides also opportunities for determining the relative immunogenicity of mismatched triplets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814283     DOI: 10.1016/j.trim.2005.01.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  21 in total

Review 1.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

2.  A structurally based approach to determine HLA compatibility at the humoral immune level.

Authors:  Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2006-09-01       Impact factor: 2.850

Review 3.  HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation.

Authors:  Adriana Zeevi; Alin Girnita; Rene Duquesnoy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Accommodation of grafts: implications for health and disease.

Authors:  Amy H Tang; Jeffrey L Platt
Journal:  Hum Immunol       Date:  2007-05-15       Impact factor: 2.850

5.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP.

Authors:  Rene J Duquesnoy; Medhat Askar
Journal:  Hum Immunol       Date:  2006-10-30       Impact factor: 2.850

Review 6.  Accommodation in organ transplantation.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Curr Opin Organ Transplant       Date:  2008-04       Impact factor: 2.640

Review 7.  Transplant nephrectomy.

Authors:  Jacob A Akoh
Journal:  World J Transplant       Date:  2011-12-24

Review 8.  Detecting adaptive immunity: applications in transplantation monitoring.

Authors:  Georg A Böhmig; Markus Wahrmann; Marcus D Säemann
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

Review 9.  Noncognate function of B cells in transplantation.

Authors:  Samuel J Balin; Jeffrey L Platt; Marilia Cascalho
Journal:  Transpl Int       Date:  2009-01-16       Impact factor: 3.782

10.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.